Io Biotech Stock Today
| IOBT Stock | USD 0.88 0.01 1.12% |
PerformanceInsignificant
| Odds Of DistressLow
|
IO Biotech is selling for under 0.88 as of the 16th of March 2025; that is 1.12 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 0.86. IO Biotech has about a 23 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 16th of December 2024 and ending today, the 16th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 5th of November 2021 | Category Healthcare | Classification Health Care |
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company was incorporated in 2014 and is based in Copenhagen, Denmark. Io Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 65.88 M outstanding shares of which 24.27 K shares are currently shorted by private and institutional investors with about 0.27 trading days to cover. More on IO Biotech
Moving together with IOBT Stock
Moving against IOBT Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
IOBT Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsIO Biotech can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand IO Biotech's financial leverage. It provides some insight into what part of IO Biotech's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
IO Biotech (IOBT) is traded on NASDAQ Exchange in USA. It is located in Ole MaalOees Vej 3, Copenhagen, Denmark, 2200 and employs 78 people. IO Biotech is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 57.9 M. IO Biotech conducts business under Biotechnology sector and is part of Health Care industry. The entity has 65.88 M outstanding shares of which 24.27 K shares are currently shorted by private and institutional investors with about 0.27 trading days to cover.
IO Biotech currently holds about 170.12 M in cash with (71.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.9, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check IO Biotech Probability Of Bankruptcy
Ownership AllocationIO Biotech secures a total of 65.88 Million outstanding shares. Over half of IO Biotech's outstanding shares are owned by institutions. These institutions are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company retains, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check IOBT Ownership Details
IOBT Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Bridgeway Capital Management, Llc | 2024-12-31 | 174 K | |
| Renaissance Technologies Corp | 2024-12-31 | 118.8 K | |
| Sectoral Asset Management Inc | 2024-12-31 | 75 K | |
| Royal Bank Of Canada | 2024-12-31 | 60 K | |
| Ubs Group Ag | 2024-12-31 | 47 K | |
| Geode Capital Management, Llc | 2024-12-31 | 33.3 K | |
| Vontobel Holding Ltd. | 2024-12-31 | 32.7 K | |
| Xtx Topco Ltd | 2024-12-31 | 28 K | |
| Pks Advisory Services, Llc | 2024-12-31 | 16 K | |
| Vivo Capital, Llc | 2024-12-31 | 6.2 M | |
| Novo A/s | 2024-12-31 | 3.4 M |
IO Biotech Historical Income Statement
IOBT Stock Against Markets
IO Biotech Corporate Management
| MaiBritt Zocca | President, Founder | Profile | |
| Qasim MD | Chief Officer | Profile | |
| Faical Miyara | Chief Officer | Profile | |
| Brian CPA | Chief Officer | Profile | |
| Amy Sullivan | Chief Officer | Profile | |
| Anders Ljungqvist | Founder | Profile | |
| Brian Burkavage | Chief Officer | Profile |
Additional Tools for IOBT Stock Analysis
When running IO Biotech's price analysis, check to measure IO Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IO Biotech is operating at the current time. Most of IO Biotech's value examination focuses on studying past and present price action to predict the probability of IO Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IO Biotech's price. Additionally, you may evaluate how the addition of IO Biotech to your portfolios can decrease your overall portfolio volatility.